Neurocrine Q4 EPS Seen Rising 125% to $2.25 on $783M Revenue
Wall Street expects Neurocrine to report Q4 EPS of $2.25 (125% yoy) on $782.91M revenue (24.7% yoy). Consensus EPS estimates slid 3.2% this month, Ingrezza sales projected at $661.61M (+7.6%), royalty revenue up 7.8% to $5.50M and other product sales down 32.8%.
1. Earnings and Revenue Estimates
Analysts forecast Neurocrine will deliver Q4 earnings of $2.25 per share, marking a 125% year-over-year increase, on revenues of $782.91 million, up 24.7% from the prior-year quarter.
2. Revision Trends
Consensus EPS estimates for the quarter have been revised downward by 3.2% over the past 30 days, reflecting analyst reassessments that may influence investor expectations ahead of the earnings release.
3. Segment Revenue Forecasts
Key metric projections include Ingrezza product sales of $661.61 million (up 7.6%), collaboration revenue of $6.46 million (down 0.6%), royalty revenue of $5.50 million (up 7.8%), and other product sales at $4.10 million (down 32.8%).